Petros Pharmaceuticals, Inc. PTPI
Set alert
0.00 USD 0.00 0.00%
As of Oct 30, 3:57 PM ET
0.002 Day range 0.0024
0.002 52-week range 0.023
- YTD
- -75.00%
- 1 year
- -90.00%
- Open
- 0.002
- Prev close
- 0.002
- Mkt cap
- 84.74K
- Vol
- 64.10K
- Avg vol
- 134.13K
- EPS
- 0.08
- P/E
- 0.03
- Div yield
- 0.00%
More statistics
- Low
- 0.002
- High
- 0.0024
- Forward P/E
- -0.26
- Beta
- 2.28
- Short ratio
- 0.72
- Inst. own
- 2.29%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.32284
- 200-d avg
- 0.5288
- 1y target
- 0.00
2Y chart
Events in this range
- Nov 13, 2024Earnings: -0.53; estimate 0; surprise —%
- May 1, 2025Split: 1 for 25
Signals (87)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Sep 30, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 30, 2026 | 1 month ago |
| SMA: Bullish | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 25, 2026 | 1 month ago |
| SMA: Bullish | Sep 24, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 11, 2026 | 1 month ago |
| SMA: Bullish | Sep 9, 2026 | 1 month ago |
| RSI: Overbought | Sep 4, 2026 | 1 month ago |
| SMA: Bullish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Aug 26, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| RSI: Overbought | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 12, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 31, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 30, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 21, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 20, 2026 | 3 months ago |
| RSI: Oversold | Jul 14, 2026 | 3 months ago |
| RSI: Oversold | Jun 30, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 17, 2026 | 4 months ago |
| SMA: Bearish | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Jun 9, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 9, 2026 | 4 months ago |
| SMA: Bearish | May 21, 2026 | 5 months ago |
| SMA: Bullish | May 8, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| MACD: Sell Signal | May 7, 2026 | 5 months ago |
| MACD: Buy Signal | May 6, 2026 | 5 months ago |
| SMA: Bullish | May 5, 2026 | 5 months ago |
| SMA: Bearish | May 4, 2026 | 6 months ago |
| MACD: Sell Signal | May 4, 2026 | 6 months ago |
| SMA: Bullish | Apr 22, 2026 | 6 months ago |
| SMA: Bearish | Apr 21, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 14, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 27, 2026 | 7 months ago |
| RSI: Oversold | Mar 27, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 26, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 13, 2026 | 7 months ago |
| SMA: Bearish | Mar 11, 2026 | 7 months ago |
| SMA: Bullish | Mar 4, 2026 | 8 months ago |
| MACD: Buy Signal | Mar 2, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 27, 2026 | 8 months ago |
| MACD: Buy Signal | Jan 6, 2026 | 9 months ago |
| RSI: Oversold | Dec 26, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 23, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 8, 2025 | 10 months ago |
| RSI: Oversold | Dec 2, 2025 | 11 months ago |
| RSI: Oversold | Nov 26, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 13, 2025 | 11 months ago |
| MACD: Buy Signal | Oct 30, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 29, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 28, 2025 | 1 year ago |
| RSI: Oversold | Oct 23, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 20, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 15, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 14, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 7, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 6, 2025 | 1 year ago |
| SMA: Bearish | Aug 27, 2025 | 1 year ago |
| SMA: Bullish | Aug 25, 2025 | 1 year ago |
| SMA: Bearish | Aug 18, 2025 | 1 year ago |
| SMA: Bullish | Aug 14, 2025 | 1 year ago |
| SMA: Bearish | Aug 5, 2025 | 1 year ago |
| SMA: Bullish | Aug 4, 2025 | 1 year ago |
| RSI: Oversold | Jul 7, 2025 | 1 year ago |
| MACD: Buy Signal | May 13, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 30, 2025 | 1 year ago |
| RSI: Oversold | Apr 30, 2025 | 1 year ago |
| RSI: Oversold | Mar 24, 2025 | 1 year ago |
| RSI: Oversold | Mar 18, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 10, 2025 | 1 year ago |
| RSI: Oversold | Feb 25, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 18, 2025 | 1 year ago |
| RSI: Oversold | Feb 18, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 14, 2025 | 1 year ago |
| SMA: Bearish | Jan 27, 2025 | 1 year ago |
| SMA: Bullish | Jan 23, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 13, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 30, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 23, 2024 | 1 year ago |
| RSI: Overbought | Dec 17, 2024 | 1 year ago |
| RSI: Oversold | Nov 26, 2024 | 1 year ago |
Key statistics
- Market cap
- 2.85M
- Enterprise value
- 3.99M
- Trailing P/E
- 0.00
- Forward P/E
- -0.26
- PEG ratio
- 0.00
- Price / sales
- 0.69
- Price / book
- 0.07
- EPS (TTM)
- -3.80
- Beta
- 2.28
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -171.24%
- Revenue (TTM)
- 4.12M
- Revenue growth
- -28.70%
- Free cash flow
- -4.10M
- Total cash
- 7.46M
- Total debt
- 7.74M
- Return on equity
- -63.77%
- Shares outstanding
- 10.01M
- Short % of float
- 2.19%
- 50-day average
- 0.32284
- 200-day average
- 0.5288
Analyst view
Consensus: none
Price target (mean) 0.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
PTPI Revenue — quarterly 0
PTPI Net income — quarterly -2.26M
PTPI EPS — quarterly -9.37
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.53 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.37 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -2.05 | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -2.17 | — | — |
| Nov 15, 2023 | Sep 1, 2023 | 0.00 | -2.31 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -1.20 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 8, 2023 | Maxim Group | init | — | Buy |
About Petros Pharmaceuticals, Inc.
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- petrospharma.com
News
- Financial Review: Petros Pharmaceuticals (NASDAQ:PTPI) & Cuprina Holdings (Cayman) (NASDAQ:CUPR)
- Head to Head Contrast: Petros Pharmaceuticals (NASDAQ:PTPI) vs. Statera Biopharma (NASDAQ:STAB)
- Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position
- Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Why Toll Brothers Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer
- Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform
- Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches
Your note
Sign in to keep a note on PTPI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERNSTEIN BRUCE T. | Director | Conversion of Exercise of derivative security | Apr 25, 2023 | 8,346 |
| BOCTOR FADY | Officer | Stock Award(Grant) | Dec 20, 2023 | 49,645 |
| BRADLEY GREG | Director | Conversion of Exercise of derivative security | Apr 25, 2023 | 8,314 |
| SILVERMAN JOSHUA N. | Director | Conversion of Exercise of derivative security | Apr 25, 2023 | 11,237 |
| WALKER WAYNE REMELL | Director | Conversion of Exercise of derivative security | Apr 25, 2023 | 8,314 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.44% | 44,221 | 12.59K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.37% | 37,517 | 10.68K | Sep 29, 2024 |
| Vanguard Group Inc | 0.32% | 31,811 | 9.05K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.32% | 32,284 | 9.19K | Sep 29, 2024 |
| Blackrock Inc. | 0.16% | 16,128 | 4.59K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.03% | 3,255 | 926 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.35% | 35,024 | 9.97K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.32% | 31,811 | 9.05K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.01% | 1,160 | 330 | Oct 30, 2024 |